Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Benitec Biopharma (BNTC) EBT (2019 - 2025)

Benitec Biopharma has reported EBT over the past 7 years, most recently at -$12.0 million for Q4 2025.

  • Quarterly results put EBT at -$12.0 million for Q4 2025, down 773.69% from a year ago — trailing twelve months through Dec 2025 was -$33.9 million (down 121.11% YoY), and the annual figure for FY2025 was -$38.5 million, down 78.26%.
  • EBT reached -$12.0 million in Q4 2025 per BNTC's latest filing, down from -$8.8 million in the prior quarter.
  • Across five years, EBT topped out at -$1.4 million in Q4 2024 and bottomed at -$12.0 million in Q4 2025.
  • Median EBT over the past 5 years was -$4.7 million (2022), compared with a mean of -$5.3 million.
  • The largest annual shift saw EBT surged 80.21% in 2024 before it tumbled 773.69% in 2025.
  • Over 5 years, EBT stood at -$4.8 million in 2021, then decreased by 15.95% to -$5.6 million in 2022, then decreased by 23.38% to -$6.9 million in 2023, then soared by 80.21% to -$1.4 million in 2024, then crashed by 773.69% to -$12.0 million in 2025.
  • Business Quant data shows EBT for BNTC at -$12.0 million in Q4 2025, -$8.8 million in Q3 2025, and -$8.8 million in Q2 2025.